Floatz logo

BUSULFANUM

B-Cell Non-Hodgkin Lymphoma

The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

305 Active assets in the B-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
ANTI-CD20/CD3 MONOCLONAL ANTIBODY REGN1979
University of Birmingham
Phase 3BBB
CYTARABINE
Children's Cancer Group, China
Phase 4BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Zanubrutinib
The First Affiliated Hospital of Soochow University
Phase 4BBB

View all 50 →

Same molecule, other indications

BUSULFANUM is also rated in:

myelodysplastic/myeloproliferative neoplasmActive
BBB
Indicative · Phase 2/3
76 / 100
View asset →
graft versus host diseaseActive
BBB
Indicative · Phase 4
74 / 100
View asset →
disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →